GSK to buy Nuvalent for USD 10.6 billion in cash, offering USD 124 per share

Nuvalent, Inc. Class A

Nuvalent, Inc. Class A

NUVL

0.00
  • GSK agreed to buy Nuvalent for USD 10.6 billion, offering USD 124 a share in cash for all outstanding Class A and Class B stock.
  • Offer implies a 40% premium to the prior close, a 26% premium to the 30-day VWAP.
  • Net of cash acquired, GSK’s investment is estimated at USD 9.4 billion; funding to come mainly from debt facilities and cash.
  • Deal adds late-stage NSCLC assets zidesamtinib and neladalkib, under FDA review with target decision dates in September 2026 and November 2026.
  • GSK expects the acquisition to lift revenue from 2027, become accretive to core operating profit in 2027, core EPS in 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-262950), on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.